about
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actionsSingle Amino Acid Variation Underlies Species-Specific Sensitivity to Amphibian Skin-Derived Opioid-like Peptides.Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenineA relationship between the hallucinogenic activity of drugs and their electronic configurationMisuse and legend in the "toad licking" phenomenon.Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic.Bufotenine: toward an understanding of possible psychoactive mechanisms.Psilocin, bufotenine and serotonin: historical and biosynthetic observations.Bufotenine reconsidered.Actions of certain amines on cerebral cortical neuronesBufotenine is able to block rabies virus infection in BHK-21 cellsStimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized miceFurther studies on the mode of action of psychotomimetic drugs: antagonism of the excitatory actions of 5-hydroxytryptamine by methylated derivatives of tryptamine.Specificity of the antibody receptor site to D-lysergamide: model of a physiological receptor for lysergic acid diethylamide.Loose associations: straight and crooked thinking and the group of schizophrenias.Mushrooms and madness. Hallucinogenic mushrooms and some psychopharmacological implications.The influence of hallucinogenic drugs upon in vivo brain levels of adenine nucleotides, phosphocreatine and inorganic phosphate in the rat.[REVIEW OF PSYCHODYSLEPTICS: I. CLASSIFICATION OF PSYCHODYSLEPTICS].The hallucinogenic basis of early Valdivia phase ceramic bowl iconography.Structure activity relations for the inhibition of 5-HT uptake into rat hypothalamic homogenates by serotonin and tryptamine analogues.Potentiation in rats of bufotenin-induced behavioral changes by chlorpromazine.Psychedelic Fauna for Psychonaut Hunters: A Mini-Review.Identity of a New World Psychoactive Toad
P2860
Q24633393-96143576-4CFE-44B5-8AEC-1A0E5B0861DDQ27318592-CDE41425-511E-4EF2-9206-92724CF00A69Q28206596-3218165E-E5F1-4E1A-B90B-EE7FA640BEACQ33805326-65ECBD6B-C982-40F2-908C-598DD2A65FE7Q34061941-CCECE61C-DABD-4857-AF2C-9194CA974C8FQ34063559-DE9B54C2-BACE-42D3-8C50-8BF782643572Q34075813-EF6A3109-8E50-4746-AE64-537E7D50EDFAQ34195176-21A0FDE1-FAF1-4F4B-BB8D-911240483C65Q34201635-F59D997A-B810-40BA-B3E6-B765FAE3CB6BQ34254856-C38F1D60-E98F-4ABB-A272-2DC7A81399AFQ34374759-12FCABE9-496B-4B93-A3C9-0828351FF7F1Q35085860-3E00E34B-D8D4-485E-AF18-E91F41CD0D44Q35601032-CF9341BD-AFE3-456E-A019-DF250C9EACBEQ37480572-0A4728D3-B806-4447-B6B1-987CC1BAD246Q38503626-7C4A86B7-A822-4AC3-A848-3871DF13EB36Q40258983-2A30CE59-1BEB-43F4-AD71-60FA12FEA169Q41814534-D802FBE5-581F-4401-909C-8DD8616AB85DQ42149152-9B1EDF39-2BEB-478B-8574-F90EBC01E4D7Q47427623-5154E184-F493-425C-BEDC-7CF4B493E583Q48627164-AEED376B-AB3F-46C6-B8CE-C791DF637297Q52329572-45A4B745-E138-49E0-A81D-0AB0D24972E8Q55386778-322D7B95-A01F-46E3-A5F4-4BBA229D17E2Q56457074-3F5E865A-CDFE-486E-AB06-5E61E0DD0753
P2860
description
1956 nî lūn-bûn
@nan
1956 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1956 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1956年の論文
@ja
1956年学术文章
@wuu
1956年学术文章
@zh-cn
1956年学术文章
@zh-hans
1956年学术文章
@zh-my
1956年学术文章
@zh-sg
1956年學術文章
@yue
name
Intravenous bufotenine injection in the human being.
@ast
Intravenous bufotenine injection in the human being.
@en
Intravenous bufotenine injection in the human being.
@nl
type
label
Intravenous bufotenine injection in the human being.
@ast
Intravenous bufotenine injection in the human being.
@en
Intravenous bufotenine injection in the human being.
@nl
prefLabel
Intravenous bufotenine injection in the human being.
@ast
Intravenous bufotenine injection in the human being.
@en
Intravenous bufotenine injection in the human being.
@nl
P1433
P1476
Intravenous bufotenine injection in the human being.
@en
P2093
P304
P356
10.1126/SCIENCE.123.3203.886
P407
P577
1956-05-01T00:00:00Z